BlackRock Health Sciences Trust (BME) Key Metrics
BME valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $578.0M
- Enterprise value
- $569.5M
- P/E (TTM)
- 5.5 10-yr median 14.1
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 5.9 10-yr median 14.3
- Price / book
- 1.0 10-yr median 0.9
- EV / EBITDA
- — 10-yr median 13.0
- Dividend yield
- 7.04% $3.15 a year
- Beta
- 0.60
BME key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsBME valuation Price multiples at each fiscal year-end price.
BME returns How much profit the business earns on the capital it uses.
BME per-share figures Results divided by the shares outstanding at year-end.
BME financial health Debt, liquidity and how easily interest is covered.
BME efficiency & capital use Working capital cycle and where the cash goes.
BME valuation history
BME returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
BME debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
BME cash returned to shareholders
BME price vs earnings per share
BME key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $534.8M | $502.8M | $564.2M | $549.3M | — | — | — | $317.1M | $324.4M | $274.6M |
| Enterprise value | $530.7M | $476.5M | $564.2M | $549.3M | — | — | — | $291.1M | $310.1M | $265.8M |
| P/E ratio | 6.9 | 21.4 | 28.2 | — | — | — | — | 14.1 | 5.4 | — |
| Price / sales | 14.8 | 20.9 | 16.2 | — | — | — | — | 13.9 | 5.3 | 10.6 |
| Price / book | 0.9 | 0.7 | 1.0 | 0.9 | — | — | — | 0.9 | 1.0 | 1.0 |
| Price / free cash flow | — | 7.7 | 17.6 | — | — | — | — | 154.6 | — | 136.7 |
| Price / operating cash flow | — | 7.7 | 17.6 | — | — | — | — | 154.6 | — | 136.7 |
| EV / sales | 14.7 | 19.8 | 16.2 | — | — | — | — | 12.7 | 5.1 | 10.3 |
| EV / EBITDA | 6.9 | 20.3 | 28.2 | — | — | — | — | 13.0 | 5.1 | — |
| EV / free cash flow | — | 7.3 | 17.6 | — | — | — | — | 142.0 | — | 132.3 |
| Earnings yield | 14.4% | 4.7% | 3.5% | −4.8% | — | — | — | 7.1% | 18.6% | −5.9% |
| Free cash flow yield | −0.8% | 13.0% | 5.7% | −0.2% | — | — | — | 0.6% | −0.4% | 0.7% |
| Dividend yield | 7.6% | 7.1% | 6.2% | 6.0% | — | — | — | 6.8% | 6.2% | 8.4% |
| Shareholder yield (dividends + buybacks) | 10.2% | 13.0% | 6.2% | 6.0% | — | — | — | 6.8% | 6.2% | 8.4% |
| Share price at fiscal year-end | $41.13 | $37.93 | $40.46 | $43.58 | $48.50 | $47.59 | $42.50 | $36.45 | $36.50 | $31.75 |
| Per share | ||||||||||
| Revenue per share | $2.78 | $1.82 | $2.50 | $0.00 | — | — | — | $2.63 | $6.83 | $2.99 |
| Earnings per share | $5.92 | $1.77 | $1.44 | −$2.10 | — | — | — | $2.58 | $6.79 | −$1.88 |
| Operating cash flow per share | −$0.33 | $4.94 | $2.30 | −$0.07 | — | — | — | $0.24 | −$0.13 | $0.23 |
| Free cash flow per share | −$0.33 | $4.94 | $2.30 | −$0.07 | — | — | — | $0.24 | −$0.13 | $0.23 |
| Cash per share | $0.38 | $2.00 | $0.00 | $0.00 | — | — | — | $2.99 | $1.62 | $1.03 |
| Book value per share | $43.71 | $57.98 | $42.18 | $47.61 | — | — | — | $40.55 | $37.34 | $31.30 |
| Tangible book value per share | $43.71 | $57.98 | $42.18 | $47.61 | — | — | — | $40.55 | $37.34 | $31.30 |
| Dividends per share | $3.12 | $2.71 | $2.52 | $2.60 | — | — | — | $2.48 | $2.25 | $2.67 |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | $0.00 | $0.00 | $0.00 |
| Debt per share | $0.07 | $0.02 | $0.00 | $0.00 | — | — | — | $0.00 | $0.01 | $0.01 |
| Shares outstanding | 13.0M | 13.3M | 13.9M | 12.6M | — | — | — | 8.7M | 8.9M | 8.6M |
| Change in shares outstanding | −1.9% | −4.9% | +10.6% | — | — | — | — | −2.1% | +2.8% | +5.2% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 11.5% | 3.5% | 3.4% | −4.3% | 3.2% | 3.4% | 8.0% | 6.6% | 20.0% | −5.7% |
| Return on invested capital (ROIC) | 9.3% | 2.8% | 1.3% | −3.4% | 3.2% | 3.4% | 8.1% | 7.0% | 20.8% | −4.7% |
| Return on assets (ROA) | 11.4% | 3.4% | 3.3% | −4.2% | 9.8% | 7.0% | 7.7% | 6.5% | 19.8% | −5.7% |
| Return on tangible assets | 13.5% | 3.0% | 3.4% | −4.4% | 9.1% | 14.3% | 4.6% | 6.3% | 18.0% | −5.9% |
| Free cash flow margin | −12.0% | 272.2% | 91.8% | — | −36.1% | −24.2% | −17.6% | 9.0% | −1.9% | 7.8% |
| Income quality (OCF / net income) | −0.06 | 2.79 | 1.60 | — | −0.36 | −0.24 | −0.18 | 0.09 | −0.02 | — |
| Financial health | ||||||||||
| Total debt | $894,332 | $299,173 | $60,686 | $2,920 | $211,572 | $102,701 | $253,802 | $4,675 | $130,910 | $126,901 |
| Cash & short-term investments | $4.9M | $26.6M | $534 | $3,118 | $960 | $211,696 | $501,313 | $26.0M | $14.4M | $8.9M |
| Net debt | −$4.0M | −$26.3M | $60,152 | −$198 | $210,612 | −$108,995 | −$247,511 | −$26.0M | −$14.3M | −$8.8M |
| Debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt / assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net debt / EBITDA | −0.05 | −1.12 | 0.00 | — | 0.00 | −0.00 | −0.00 | −1.16 | −0.24 | — |
| Current ratio | — | — | −0.00 | 0.01 | 0.00 | 0.05 | 0.71 | 0.90 | 0.11 | 0.66 |
| Quick ratio | — | — | −0.00 | 0.01 | −2.48 | 0.05 | −2.37 | 0.90 | 0.11 | 0.66 |
| Working capital | — | — | −$8.0M | −$230,080 | −$12.5M | −$8.2M | −$444,954 | −$91,057 | −$2.5M | −$976,240 |
| Invested capital | $564.3M | $742.3M | $588.2M | $600.2M | $626.0M | $3.02B | $1.64B | $326.7M | $317.6M | $261.9M |
| Tangible asset value | $568.3M | $768.6M | $588.1M | $600.2M | $625.8M | $545.9M | $1.64B | $352.7M | $331.9M | $270.7M |
| Net current asset value | $3.5M | $20.5M | −$8.0M | −$5.9M | −$23.0M | −$8.2M | −$92.4M | −$2.0M | −$2.5M | −$976,240 |
| Graham number | $76.30 | $48.05 | $36.91 | — | — | — | — | $48.51 | $75.53 | — |
| Graham net-net per share | $0.26 | $1.62 | −$0.49 | −$0.33 | — | — | — | $2.74 | $1.34 | $0.85 |
| Capital allocation | ||||||||||
| Dividends paid | $40.6M | $35.9M | $35.1M | $32.7M | $29.0M | $25.6M | $23.2M | $21.6M | $20.0M | $23.0M |
| Share buybacks (net) | $14.0M | $29.5M | $0 | $2,920 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividend payout ratio | 52.8% | 153.2% | 175.3% | — | 49.1% | 32.2% | 29.1% | 96.3% | 33.1% | — |
| Dividends + buybacks / free cash flow | — | 99.9% | 109.6% | — | — | — | — | — | — | — |
| Capex / revenue | 0.0% | 0.0% | 0.0% | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Capex / operating cash flow | — | 0.0% | 0.0% | — | — | — | — | 0.0% | — | 0.0% |
| Capex / depreciation | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
| SG&A / revenue | 1.2% | 1.5% | 0.9% | — | 0.6% | 0.5% | 0.4% | 1.4% | 0.5% | 12.3% |
| Efficiency | ||||||||||
| Days sales outstanding | 8.2 | 21.0 | 20.6 | — | 10.9 | 2.2 | 3.2 | 9.1 | 5.9 | 27.4 |
| Days of inventory on hand | — | — | — | — | 925.1 | — | 206.3 | — | — | — |
| Days payables outstanding | 22.9 | 2,307,487.9 | — | 390.5 | 376.2 | 60.3 | 107.9 | 46.0 | 21.9 | 48.9 |
| Cash conversion cycle (days) | -14.7 | -2,307,466.9 | — | — | 559.7 | 114.6 | 101.6 | -36.9 | -16.0 | -21.6 |
| Receivables turnover | 44.54 | 17.37 | 17.69 | 0.00 | 33.58 | 168.60 | 113.73 | 40.19 | 61.82 | 13.34 |
| Payables turnover | 15.96 | 0.00 | — | 0.93 | 0.97 | 6.05 | 3.38 | 7.94 | 16.65 | 7.46 |
| Inventory turnover | — | — | — | — | 0.39 | — | 1.77 | — | — | — |
| Asset turnover | 0.05 | 0.04 | 0.06 | 0.00 | 0.10 | 0.07 | 0.08 | 0.07 | 0.20 | 0.09 |
| Average receivables | $811,809 | $1.4M | $2.0M | $2.8M | $1.8M | $475,035 | $705,968 | $569,505 | $982,444 | $1.9M |
| Average payables | $352,533 | $493,107 | — | $6.4M | $6.3M | $817,445 | $1.2M | $464,291 | $196,632 | $402,516 |
| Average inventory | — | — | — | $15.5M | $15.5M | $2.3M | $2.3M | $0 | $0 | $0 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from BME's annual financial statements (latest annual report filed December 31, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
BME valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), BlackRock Health Sciences traded at 6.9 times earnings, against a 10-year median of 14.1. Based on the latest twelve months, the trailing P/E is 5.5. BlackRock Health Sciences earned a return on equity of 11.5% and a return on invested capital of 9.3% in fiscal 2025. It ended the year with $0.9 million of debt and $4.9 million in cash and short-term investments, a net cash position of $4.0 million. It returned $54.6 million to shareholders: $40.6 million in dividends and $14.0 million in share buybacks. The share count rose 50.3% from 8.6M to 13.0M over 9 years.
See the BME income statement, the BME chart for price history, or the BME stock overview for the latest quote and news.
BME key metrics FAQ
What is BlackRock Health Sciences's P/E ratio?
BlackRock Health Sciences's trailing P/E ratio is 5.5 based on the last twelve months of earnings (as of October 17, 2026). At the end of fiscal 2025 it was 6.9, compared with a 10-year median of 14.1.
What is BlackRock Health Sciences's EV/EBITDA?
BlackRock Health Sciences's enterprise value was 6.9 times EBITDA at the end of fiscal 2025 (enterprise value $530.7 million, EBITDA $77.0 million).
What is BlackRock Health Sciences's return on equity?
BlackRock Health Sciences's return on equity (ROE) was 11.5% in fiscal 2025: net income of $77.0 million on average shareholders' equity of $668.4 million.
What is BlackRock Health Sciences's ROIC?
BlackRock Health Sciences's return on invested capital was 9.3% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does BlackRock Health Sciences have?
BlackRock Health Sciences had total debt of $0.9 million at the end of fiscal 2025, a debt-to-equity ratio of 0.00 and more cash than debt.
What is BlackRock Health Sciences's dividend yield?
BlackRock Health Sciences's forward dividend yield is 7.04%. BlackRock Health Sciences paid $40.6 million in dividends in fiscal 2025 ($3.12 per share), a payout ratio of 52.8%.
Does BlackRock Health Sciences buy back its shares?
Yes. BlackRock Health Sciences spent $14.0 million on net share repurchases in fiscal 2025 Shares outstanding changed −1.9% over the year, to 13.0M..
What is BlackRock Health Sciences's free cash flow yield?
BlackRock Health Sciences generated -$4.4 million of free cash flow in fiscal 2025, a free cash flow yield of −0.8% on its market value at year-end ($534.8 million).